

MEDEUROPA COMPLETES FIRST GERMAN INVESTMENT WITH THE ACQUISITION OF MVZ GAMMA KNIFE GMBH

MedEuropa AG (“MedEuropa”), a European cancer care company, has completed its acquisition of MVZ Gamma Knife GmbH (“MVZ Gamma Knife”), the leading provider of brain radiosurgery treatments in Germany. The transaction is MedEuropa’s first investment in Germany. Financial details have not been disclosed.

MVZ Gamma Knife operates two sites in the areas of Düsseldorf and Hannover. Since its foundation twenty years ago, MVZ Gamma Knife has successfully treated more than 10,000 patients and has established itself as one of the largest and most experienced operators of Gamma Knife^{®1} technology in Europe.

MedEuropa is pleased to have partnered with MVZ Gamma Knife’s former shareholding doctors, ensuring continuity of high quality care for patients and referring physicians. Dr Gerhard Horstmann, a worldwide expert in radiosurgery who has led the operations for over fifteen years, will continue to lead the clinics.

Gamma Knife is a highly accurate non-invasive treatment for benign and malign tumours located in the head and neck, such as brain metastases, providing treatment in a single, painless, ambulatory session. As the incidence of brain metastases continues to increase, MedEuropa is committed to further developing the capacity of MVZ Gamma Knife to treat more patients across Germany.

In addition to this investment in Gamma Knife, MedEuropa is actively considering acquisition opportunities within traditional radiotherapy, with the aim of building a platform in Western Europe, initially focusing on Germany and France.

Contact

Ralph Hefti, CEO

ralph.hefti@medeuropa.org

About MVZ Gamma Knife

Founded in 1998, MVZ Gamma Knife operates two sites in the areas of Düsseldorf (Krefeld) and Hannover. Since foundation, it has successfully treated more than 10,000 patients and has established itself as one of the largest and most experienced operators of Gamma Knife^{®1} technology in Europe. Please visit www.gamma-knife.de/en/ for more information.

About MedEuropa

Founded in 2017, MedEuropa is committed to providing state of the art cancer treatment across Europe, with a strong focus on radiotherapy. MedEuropa seeks to

¹ Gamma Knife is a registered trade-mark of Elekta (<https://gammaknife.com/what-is-gamma-knife/>)

partner with leading medical professionals, who share its vision of improving the provision and quality of cancer treatment. In Western European markets, MedEuropa is focused on partnership and acquisition opportunities. In parallel, MedEuropa is pursuing a greenfield strategy in the under-supplied Romanian market, where it recently opened its first center and is developing further sites. Please visit www.medeuropa.org for more information.

About Telemos Capital

Telemos is a private investment firm founded in 2017 with a strong focus on healthcare services. Geographically the investment mandate is pan-European. The Telemos team consists of an internationally diverse group of experienced investors, based in London, UK. Telemos is actively working to build its portfolio of attractive investments in European growth companies. Please visit www.telemoscapital.com for more information.

May 8th, 2019.